Business Wire

CIRIUM

5.10.2022 09:01:49 CEST | Business Wire | Press release

Share
Vueling and Cirium Sign a Deal for Cirium Sky, to Dramatically Improve Airline Operational Performance

Vueling, an airline which forms part of IAG (International Airlines Group), has signed a landmark deal with Cirium, the aviation analytics company, to improve airline operational efficiencies through the Cirium Sky managed data warehouse and analytics solution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005079/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Vueling and Cirium sign a deal for Cirium Sky, to dramatically improve airline operational performance (Photo: Business Wire)

The multi-year deal provides Vueling, with access to Cirium’s new data aviation warehouse and analytics capability.

This partnership will allow the airline to gain a unique insight from over 25 operational factors, and ultimately provide a best-in-traveller experience.

Cirium Sky will enable more effective flight planning, especially around disruption, to minimize delays for its customers.

Jeremy Bowen, Cirium CEO, said: “Our aviation data warehouse, Cirium Sky, is critical in supporting Vueling’s digital transformation initiatives and will enable the airline to improve flight operations, reduce travel delays and set the stage for operational excellence.”

Vueling is viewed by Cirium as the agile and innovative leader in IAG thanks to the implementation of several initiatives, including Vueling Transform, to unlock its full potential through digitization and low-cost leadership.

Oliver Iffert, Vueling Chief Operations Officer , said: “Coming out of the pandemic, Vueling is emerging even more efficient and competitive as we prioritize actionable insights backed by a wealth of data and context.”

“Data is key to assessing our operations and identifying ways to provide a passenger experience that stands out.”

“Using Cirium Sky, Vueling can plan flights more effectively and analyze flight delays based on accurate data. We will, as a result, drive a reduction in delays and minimize disruptions.”

The move to Cirium Sky transitions Vueling from using multiple data providers and data held in siloed systems to a single source of aviation data and analytics.

This strategic data and analytics partnership provides the airline with access to the industry’s largest data warehouse, which has a 360-degree view of flights, as well as prescriptive and predictive analytics to anticipate future operational challenges.

Added Bowen: “Improving operations is not only key for the traveller experience but also for tackling the liquidity issues and capacity recovery that airlines are facing in the wake of COVID-19.“

“By democratizing data and enabling smarter and faster decision making, airlines would see huge savings. We are delighted to partner with Vueling and drive value for their business.”

Cirium Sky is purpose-built to enable airlines, airports, financial institutions, aircraft manufacturers, and travel distributors to unlock the value in aviation data.

Find out more about Cirium Sky.

Ends

About Cirium

Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com

About Vueling

Vueling, a company which forms part of IAG, is key in connectivity in Spain, the largest domestic market in Europe. For this winter 2022, the company has a network of more than 240 short and medium-haul routes in Europe, North Africa and the Middle East, which are operated with a fleet of Airbus A319, A320, A320neo and A321 models. In 2021, Vueling has won the World Airline Awards as the "Best Low Cost Airline in Europe".

As part of IAG, Vueling shares the vision of leading the field of sustainability within the global airline industry. That is why the company develops all its actions within the framework of the "Flightpath Net Zero" program, through which the goal of achieving net zero CO2 emissions in 2050 has been established.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005079/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye